AKTX
What one share of Akari Therapeutics holds
Pharmaceutical Preparations
We are an oncology company developing next-generation antibody-drug conjugates (“ADCs”) designed around novel, proprietary cancer-killing toxins (“payloads”). We believe these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development.
Akari Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.00 |
|---|---|
| Cash and investments | $0.00 |
| Book value | $0.00 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$0.02 | $0.00 | −$0.02 | — | $0.03 |
| 2017 | — | −$0.03 | $0.00 | −$0.03 | — | $0.01 |
| 2018 | — | −$0.01 | $0.00 | −$0.01 | — | — |
| 2019 | — | −$0.01 | $0.00 | −$0.01 | — | $0.00 |
| 2020 | — | −$0.01 | — | −$0.01 | — | $0.00 |
| 2021 | — | −$0.00 | — | −$0.00 | — | $0.00 |
| 2022 | — | −$0.00 | — | −$0.00 | — | $0.00 |
| 2023 | — | −$0.00 | — | −$0.00 | — | $0.00 |
| 2024 | — | −$0.00 | — | −$0.00 | — | — |
| 2025 | — | −$0.00 | — | −$0.00 | — | $0.00 |